Drug Trial Radar · NCT04718103
A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
Last checked: Nov 20, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
397
Actual
Start
Feb 4, 2021
Primary completion
Apr 11, 2024
Study completion Apr 11, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.
Conditions
- Asthma
Interventions
GSK3511294Biological
GSK3511294 was administered using a pre-filled syringe.
PlaceboBiological
Placebo was administered as normal saline using a pre-filled syringe.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Clinically Significant Exacerbations up to 52 WeeksTime frame: Up to Week 52
Locations
129 sites in 11 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Alabaster, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Beverly Hills, California
GSK Investigational Site
Lancaster, California
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Lafayette, Colorado
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami Lakes, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Evanston, Illinois
GSK Investigational Site
Columbia, Maryland
GSK Investigational Site
Dearborn, Michigan
GSK Investigational Site
Ypsilanti, Michigan
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Northfield, New Jersey
GSK Investigational Site
Toms River, New Jersey
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Huntersville, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Edmond, Oklahoma
GSK Investigational Site
Altoona, Pennsylvania
GSK Investigational Site
DuBois, Pennsylvania
GSK Investigational Site
Hershey, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Rapid City, South Dakota
GSK Investigational Site
Allen, Texas
GSK Investigational Site
Boerne, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Bellingham, Washington
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.